The Global Reye’s Syndrome Market Increasing Prevalence of Influenza and Growing Adolescent Population Will Grow CAGR of ~7.20% during Forecasted Period 2017-2023

Pune, India, January 2018 /MRFR Press Release/- Market Research Future published a half-cooked research report on global Reye’s syndrome market.

Market Highlights

Reye’s syndrome is a rare disease that causes swelling of the liver and brain. Increasing prevalence of influenza and rising teenage population are the major drivers of the market growth. Moreover, increasing per capita healthcare expenditure and developing biotechnology & pharmaceutical industries within the developing economies across the world are estimated to boost the market growth during the forecasted period. However, lack of awareness, limited treatment options, and FDA approvals may restrain the market growth during the forecast period.

Segmentation

The global Reye’s syndrome market is segmented on the basis of diagnosis, treatment and end users.

On the basis of the diagnosis, the market is segmented into tests, biopsy, imaging, and others. The test segment is sub-segmented into blood tests, urine tests, and others. The biopsy segment is sub-segmented into liver biopsy, skin biopsy, and others. The imaging segment is sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and others.

On the basis of the treatment, the market is categorized into electrolytes and fluids, corticosteroids, ammonia detoxicants, insulin, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research laboratories, diagnostic centers, and others.

Regional Analysis

The Americas hold the major share of the global Reye’s syndrome market. The presence of a well-developed healthcare sector, rising healthcare expenditures, and growing adolescent population are the major drivers of the market growth within the region.

Europe holds the second largest market for Reye’s syndrome. Availability of funds for research and government support for research & development are the major drives for the growth of the market within the region.

Asia Pacific is the fastest growing region for the market due to the presence of continuously developing economies. Moreover, growing the pharmaceutical sector and expanding healthcare sector is estimated to drive the market growth within the region.

On the other hand, the Middle East & Africa has the least share of the global Reye’s syndrome market. Presence of poor economies and stringent government policies, especially within the African region, are restraining the market growth within the region. A majority of the market of this region is held by the Middle East.

Key Players

General Electric Company (U.S.), Siemens Healthcare GmbH (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), Koninklijke Philips N.V. (The Netherlands), NeuroLogica Corp. (U.S.), Sumitomo Corporation (Japan), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K), Eli Lilly and Company (U.S.), Biocon (India), Ypsomed (Switzerland), BD (U.S.), ARGON MEDICAL (U.S.), and others.

Browse Full Report @ https://www.marketresearchfuture.com/reports/reye-s-syndrome-market-5302 .